Insulet (NASDAQ:PODD – Get Rating) posted its quarterly earnings results on Thursday. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.14, Briefing.com reports. Insulet had a net margin of 0.35% and a return on equity of 20.55%. The firm had revenue of $358.10 million […]
Shares of Insulet Co. (NASDAQ:PODD – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month target […]
Arcadia Wealth Management LLC acquired a new position in shares of Insulet Co. (NASDAQ:PODD – Get Rating) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 776 shares of the medical instruments supplier’s stock, valued at approximately $228,000. A number of other hedge funds and […]
FourThought Financial Partners LLC bought a new position in Insulet Co. (NASDAQ:PODD – Get Rating) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 2,456 shares of the medical instruments supplier’s stock, valued at approximately $723,000. Several other hedge funds have also added to or […]
Insulet Co. (NASDAQ:PODD – Get Rating) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 3,900,000 shares, a drop of 19.6% from the March 31st total of 4,850,000 shares. Based on an average trading volume of 828,000 shares, the days-to-cover […]